MAP Kinase Inhibitors Patent - Washington University

EPO published patent application EP4219489A2 for MAP kinase inhibitor compounds and their methods of use. The patent, filed by Washington University (St. Louis, MO), covers heterocyclic compounds falling under IPC classifications C07D 401/12, C07D 405/12, C07D 407/14, C07D 409/14, C07D 413/12, C07D 417/14, and others. Designated states include all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The therapeutic indications covered include respiratory conditions (A61P 11/00), antimicrobial applications (A61P 31/00), and anticancer uses (A61P 35/00).

Pharmaceutical companies developing kinase inhibitor therapies should review this patent for freedom-to-operate considerations. Patent monitoring services should flag this publication for competitive intelligence tracking. The patent is now publicly available in the EPO register and provides protection for the disclosed compounds and methods in the designated contracting states.